MISSISSAUGA, Ontario, Sept. 14, 2022 (GLOBE NEWSWIRE) — BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is happy to announce that it has been chosen to current at the 7th annual MicroCap Leadership Summit on Friday, September 16th, 2022.
Mr. René Goehrum, President and CEO of BioSyent, will current to traders an outline of BioSyent’s business and company actions. The MicroCap Leadership Summit is attended by retail and institutional traders from round the world. BioSyent was one in every of twelve corporations chosen to current at this yr’s occasion. For extra details about the MicroCap Leadership Summit, please go to: http://microcapclub.com/summit/.
About BioSyent Inc.
Listed on the TSX Venture Exchange underneath the buying and selling image “RX”, BioSyent is a worthwhile growth-oriented specialty pharmaceutical firm targeted on in-licensing or buying progressive pharmaceutical and different healthcare merchandise which were efficiently developed, are secure and efficient, and have a confirmed observe report of bettering the lives of sufferers. BioSyent helps the healthcare professionals that deal with these sufferers by advertising its merchandise by way of its group, specialty and worldwide business items.
As of the date of this press launch, the Company has 12,186,561 widespread shares excellent.
For a direct market quote for the TSX Venture Exchange and different Company monetary info please go to www.tmxmoney.com.
For additional info please contact:
Mr. René C. Goehrum
President and CEO
BioSyent Inc.
E-Mail: [email protected]
Phone: 905-206-0013
Web: www.biosyent.com
This press launch might comprise info or statements which are forward-looking. The contents herein characterize our judgment, as at the launch date, and are topic to dangers and uncertainties that will trigger precise outcomes or outcomes to be materially completely different from the forward-looking info or statements. Potential dangers might embrace, however should not restricted to, these related to medical trials, product growth, future income, operations, profitability and acquiring regulatory approvals.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that time period is outlined in the insurance policies of the TSX Venture Exchange) accepts duty for the adequacy or accuracy of this press launch.
